首页> 外文期刊>Clinical & translational oncology : >Heterotopic ossification after total hip arthroplasty (THA) in congenital hip disease: comparison of two different prophylactic protocols.
【24h】

Heterotopic ossification after total hip arthroplasty (THA) in congenital hip disease: comparison of two different prophylactic protocols.

机译:先天性髋部疾病全髋关节置换术(THA)后的异位骨化:两种不同预防方案的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: We aimed to evaluate retrospectively the efficacy of combined postoperative radiotherapy and indomethacin compared to indomethacin alone for the prevention of heterotopic ossification (HO) in high-risk patients with congenital disease of hip (CDH) undergoing total hip arthroplasty (THA). MATERIALS AND METHODS: Fifty-five patients received indomethacin alone (Group A), while 44 patients received the combined protocol (Group B). Patients >or=55 years were enrolled in Group B and those younger than 55 years in Group A. Patients were evaluated radiologically for the presence of HO 6 months after the operation. RESULTS: The incidence of HO in Group A was 34.5% (95% confidence interval 22.2-48.6%), while the respective incidence in Group B patients was 27.3% (95% CI 15.0- 42.8%). The difference was not statistically significant (p=0.5). No significant treatment-related side effects were reported. CONCLUSIONS: This is the first study evaluating the impact of HO prophylaxis in an immiscible population of patients with secondary arthritis due to CDH undergoing THA. Further future randomised evidence is required in order to ascertain the observed trend towards improved efficacy of the combined protocol for HO development.
机译:简介:我们的目的是回顾性评估术后放疗联合吲哚美辛与单独使用吲哚美辛相比在先天性全髋关节置换术(THA)的高危先天性髋关节疾病(CDH)患者中预防异位骨化(HO)的疗效。材料与方法:55例患者单独接受消炎痛(A组),而44例患者接受联合方案(B组)。年龄≥55岁的患者入组B,年龄小于55岁的患者入组A。对患者术后6个月是否存在HO进行放射学评估。结果:A组HO的发生率为34.5%(95%置信区间为22.2-48.6%),而B组患者的HO发生率为27.3%(95%CI 15.0-42.8%)。差异无统计学意义(p = 0.5)。没有明显的治疗相关的副作用的报道。结论:这是第一项评估HO预防对因CDH经历THA而引起的继发性关节炎不相溶人群的影响的第一项研究。为了确定观察到的趋势,即改进HO开发的联合方案疗效的趋势,还需要进一步的未来随机证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号